ArticleEpilepsia open2026
Distinct medial temporal volumetric signatures in extra-medial temporal lobe lesional epilepsy.
Article in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Distinct medial temporal volumetric signatures in extra-medial temporal lobe lesional epilepsy.Epilepsia open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo quantify amygdala and hippocampal volumetric asymmetries in patients with drug-resistant epilepsy (DRE) and extra-medial temporal lesions (EMTLs) and to assess the prevalence of structural alterations relative to drug-resistant temporal lobe epilepsy (TLE), extratemporal lobe epilepsy (ETLE), and healthy individuals.
methodsRetrospective cross-sectional study of 298 participants evaluated at the NIH Clinical Center (2004-2023), including 252 patients with focal DRE and 46 healthy volunteers. Of the DRE cohort, 63 had lateralized EMTL (48 left, 15 right). High-resolution brain MRIs were segmented and analyzed to obtain normalized amygdala and hippocampal volumes. An asymmetry index (AI) assessed directionality, and absolute AI measured magnitude. Atrophy and hypertrophy were defined relative to healthy medians using robust dispersion thresholds. Group comparisons incorporated correction for multiple testing.
resultsDual pathology with mesial temporal sclerosis was radiologically identified in 20.6% of EMTL cases, predominantly ipsilateral. Adjusted amygdala and hippocampal volumes did not differ significantly across groups, and consistent amygdala atrophy was not observed. Left EMTL showed increased hippocampal asymmetry magnitude and a 39.6% prevalence of ipsilateral hippocampal atrophy, comparable to left TLE (34%). Right EMTL showed loss of the physiologic left-smaller-than-right hippocampal pattern, with hypertrophy in the right amygdala (40%), left amygdala (46.7%), and contralateral hippocampus (40%), as well as ipsilateral hippocampal atrophy in 26.7%. SIGNIFICANCE: We found mesial temporal volumetric changes in a significant proportion of EMTL patients. Directional, magnitude, and outlier-based analyses help disentangle coexisting atrophy and hypertrophy, revealing potential compensatory network-level changes in EMTL-associated DRE not previously identified. PLAIN LANGUAGE SUMMARY: This study looked at changes in two brain structures, the amygdala and hippocampus, in people with treatment-resistant epilepsy associated with lesions outside the medial temporal lobe. We found that patients with lesions on the left side often had a small left hippocampus, while those with right-sided lesions showed more complex patterns, including enlargement of both the amygdala and left hippocampus and less frequent small right hippocampus. These findings suggest that detailed measurements of brain asymmetry can uncover changes missed by standard assessment and may help doctors better locate seizure activity and plan treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.